Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Importance and problems of intraperitoneal chemotherapy].

R Jakesz1

  • 1I. Chirurgischen Universitätsklinik Wien.

Wiener Medizinische Wochenschrift (1946)
|April 30, 1990
PubMed
Summary

Intraperitoneal chemotherapy offers high local drug concentrations for peritoneal carcinosis, significantly reducing its incidence. While survival benefits are pending, this innovative approach shows promise in managing minimal residual disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.

Breast (Edinburgh, Scotland)·2019
Same author

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.

British journal of cancer·2014
Same author

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).

Annals of oncology : official journal of the European Society for Medical Oncology·2013

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Peritoneal carcinosis presents challenges in defining remission and treatment efficacy.
  • Intraperitoneal chemotherapy (IP chemotherapy) is an emerging modality for managing peritoneal carcinosis.

Purpose:

  • To evaluate the efficacy and safety of intraperitoneal chemotherapy for peritoneal carcinosis.
  • To explore the pharmacokinetic advantages and clinical outcomes of IP chemotherapy.

Summary:

  • IP chemotherapy achieves significantly higher local cytotoxic drug concentrations compared to systemic administration, potentially reaching 1000 times serum levels.
  • Totally implantable systems minimize infection risks associated with traditional Tenckhoff catheters.
  • While adjuvant trials did not demonstrate improved survival, IP chemotherapy significantly decreased the incidence of peritoneal carcinosis, particularly in minimal residual disease (30-50% remission rates).

Impact:

  • IP chemotherapy enhances local drug delivery, improving treatment for peritoneal carcinosis.
  • Reduced infection rates and high local drug concentrations represent key advantages.
  • Future research directions include early postoperative administration and combination therapies with biological response modifiers.

Related Experiment Videos